236 related articles for article (PubMed ID: 34991617)
21. CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse.
Zhu W; Xie K; Xu Y; Wang L; Chen K; Zhang L; Fang J
Virus Res; 2016 Jun; 217():125-32. PubMed ID: 27049051
[TBL] [Abstract][Full Text] [Related]
22. An Effective Molecular Target Site in Hepatitis B Virus S Gene for Cas9 Cleavage and Mutational Inactivation.
Li H; Sheng C; Liu H; Liu G; Du X; Du J; Zhan L; Li P; Yang C; Qi L; Wang J; Yang X; Jia L; Xie J; Wang L; Hao R; Xu D; Tong Y; Zhou Y; Zhou J; Sun Y; Li Q; Qiu S; Song H
Int J Biol Sci; 2016; 12(9):1104-13. PubMed ID: 27570484
[TBL] [Abstract][Full Text] [Related]
23. Targeted HBx gene editing by CRISPR/Cas9 system effectively reduces epithelial to mesenchymal transition and HBV replication in hepatoma cells.
Rawal P; Tripathi DM; Hemati H; Kumar J; Tyagi P; Sarin SK; Nain V; Kaur S
Liver Int; 2024 Feb; 44(2):614-624. PubMed ID: 38105495
[TBL] [Abstract][Full Text] [Related]
24. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
[TBL] [Abstract][Full Text] [Related]
25. [Antiviral Activity of CRISPR/Cas9 Ribonucleoprotein Complexes on a Hepatitis B Virus Model In Vivo].
Kostyusheva AP; Brezgin SA; Ponomareva NI; Goptar IA; Nikiforova AV; Gegechkori VI; Poluektova VB; Turkadze KA; Sudina AE; Chulanov VP; Kostyushev DS
Mol Biol (Mosk); 2022; 56(6):884-891. PubMed ID: 36475475
[TBL] [Abstract][Full Text] [Related]
26. Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9.
Kostyushev D; Kostyusheva A; Brezgin S; Ponomareva N; Zakirova NF; Egorshina A; Yanvarev DV; Bayurova E; Sudina A; Goptar I; Nikiforova A; Dunaeva E; Lisitsa T; Abramov I; Frolova A; Lukashev A; Gordeychuk I; Zamyatnin AA; Ivanov A; Chulanov V
Mol Ther Nucleic Acids; 2023 Mar; 31():482-493. PubMed ID: 36865089
[TBL] [Abstract][Full Text] [Related]
27. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.
Kennedy EM; Bassit LC; Mueller H; Kornepati AVR; Bogerd HP; Nie T; Chatterjee P; Javanbakht H; Schinazi RF; Cullen BR
Virology; 2015 Feb; 476():196-205. PubMed ID: 25553515
[TBL] [Abstract][Full Text] [Related]
28. Lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition.
Suzuki Y; Onuma H; Sato R; Sato Y; Hashiba A; Maeki M; Tokeshi M; Kayesh MEH; Kohara M; Tsukiyama-Kohara K; Harashima H
J Control Release; 2021 Feb; 330():61-71. PubMed ID: 33333121
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Hepatitis B Virus with the Help of CRISPR/Cas9 Technology.
Noor S; Rasul A; Iqbal MS; Ahmed B; Akash MSH; Qadir MI
Crit Rev Eukaryot Gene Expr; 2020; 30(3):273-278. PubMed ID: 32749114
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome.
Liu X; Hao R; Chen S; Guo D; Chen Y
J Gen Virol; 2015 Aug; 96(8):2252-2261. PubMed ID: 25904148
[TBL] [Abstract][Full Text] [Related]
31. CRISPR/Cas9 for hepatitis B virus infection treatment.
Cai B; Chang S; Tian Y; Zhen S
Immun Inflamm Dis; 2023 May; 11(5):e866. PubMed ID: 37249290
[TBL] [Abstract][Full Text] [Related]
32.
Kayesh MEH; Hashem MA; Kohara M; Tsukiyama-Kohara K
Front Microbiol; 2022; 13():953218. PubMed ID: 35847068
[TBL] [Abstract][Full Text] [Related]
33. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
34. Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.
Givens BE; Naguib YW; Geary SM; Devor EJ; Salem AK
AAPS J; 2018 Oct; 20(6):108. PubMed ID: 30306365
[TBL] [Abstract][Full Text] [Related]
35. Biomimetic Mineralization-Based CRISPR/Cas9 Ribonucleoprotein Nanoparticles for Gene Editing.
Li S; Song Z; Liu C; Chen XL; Han H
ACS Appl Mater Interfaces; 2019 Dec; 11(51):47762-47770. PubMed ID: 31773942
[TBL] [Abstract][Full Text] [Related]
36. ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells.
Scott T; Moyo B; Nicholson S; Maepa MB; Watashi K; Ely A; Weinberg MS; Arbuthnot P
Sci Rep; 2017 Aug; 7(1):7401. PubMed ID: 28785016
[TBL] [Abstract][Full Text] [Related]
37. Targeting hepatitis B virus cccDNA using CRISPR/Cas9.
Kennedy EM; Kornepati AV; Cullen BR
Antiviral Res; 2015 Nov; 123():188-92. PubMed ID: 26476375
[TBL] [Abstract][Full Text] [Related]
38. Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus.
Sakuma T; Masaki K; Abe-Chayama H; Mochida K; Yamamoto T; Chayama K
Genes Cells; 2016 Nov; 21(11):1253-1262. PubMed ID: 27659023
[TBL] [Abstract][Full Text] [Related]
39. Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus.
Zhen S; Hua L; Liu YH; Gao LC; Fu J; Wan DY; Dong LH; Song HF; Gao X
Gene Ther; 2015 May; 22(5):404-12. PubMed ID: 25652100
[TBL] [Abstract][Full Text] [Related]
40. One-Vector System for Multiplexed CRISPR/Cas9 against Hepatitis B Virus cccDNA Utilizing High-Capacity Adenoviral Vectors.
Schiwon M; Ehrke-Schulz E; Oswald A; Bergmann T; Michler T; Protzer U; Ehrhardt A
Mol Ther Nucleic Acids; 2018 Sep; 12():242-253. PubMed ID: 30195763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
